文献速递睡眠呼吸障碍小儿耳鼻咽喉咽喉与嗓音

青少年唐氏综合征合并阻塞性睡眠呼吸暂停患者上气道刺激疗效评估

Evaluation of Upper Airway Stimulation for Adolescents With Down Syndrome and Obstructive Sleep Apnea.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2022-01-01

这项前瞻性单组多中心队列研究纳入42例腺样体扁桃体切除术后持续重度OSA且不耐受气道正压的唐氏综合征青少年,评估上气道刺激的安全性与有效性。术后12个月AHI平均下降12.9次/小时,治疗应答率65.9%,73.2%患者AHI低于10次/小时,最常见并发症为暂时性舌或口腔不适(5例,11.9%)。

要点

  • 上气道刺激可使唐氏综合征青少年重度OSA患者AHI平均下降12.9次/小时(95%CI -17.0至-8.7)。
  • 12个月治疗应答率65.9%(27/41),73.2%(30/41)患者AHI低于10次/小时。
  • 最常见并发症为暂时性舌或口腔不适,发生率为11.9%(5例),再手术率为4.8%(2例)。

核心结论

  • 上气道刺激可安全用于42例腺样体扁桃体切除术后持续重度OSA且不耐受气道正压的唐氏综合征青少年,不良事件可接受,治疗应答率和生活质量改善率较高。

研究设计与样本

  • 前瞻性单组多中心队列研究,随访1年,于2015年4月1日至2021年7月31日纳入42例连续转诊的腺样体扁桃体切除术后持续重度OSA的唐氏综合征青少年患者。

主要发现

  • 42例患者中28例为男性(66.7%),平均(SD)年龄15.1(3.0)岁,AHI平均(SD)下降12.9(13.2)次/小时(95%CI -17.0至-8.7次/小时)。
  • 以AHI下降50%定义治疗应答,12个月应答率为65.9%(27/41),73.2%(30/41)患者12个月AHI低于10次/小时。
  • 最常见并发症为暂时性舌或口腔不适,发生于5例患者(11.9%),再手术率为4.8%(n=2)。
  • OSA-18总分平均(SD)改善34.8(20.3)(95%CI -42.1至-27.5),Epworth嗜睡量表评分平均(SD)改善5.1(6.9)(95%CI -7.4至-2.8)。
  • 每夜治疗平均(SD)时长为9.0(1.8)小时,40例患者(95.2%)每夜使用设备至少4小时。

关键数值与推荐

  • 主要结局为安全性和基线至术后12个月AHI的变化;治疗应答定义为AHI下降50%。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with Down syndrome have a high incidence of persistent obstructive sleep apnea (OSA) and limited treatment options. Upper airway hypoglossal stimulation has been shown to be effective for adults with OSA but has not yet been evaluated for pediatric populations. OBJECTIVE: To evaluate the safety and effectiveness of upper airway stimulation for adolescent patients with Down syndrome and severe OSA. DESIGN, SETTING, AND PARTICIPANTS: This prospective single-group multicenter cohort study with 1-year follow-up was conducted between April 1, 2015, and July 31, 2021, among a referred sample of 42 consecutive adolescent patients with Down syndrome and persistent severe OSA after adenotonsillectomy. INTERVENTION: Upper airway stimulation. MAIN OUTCOMES AND MEASURES: The prespecified primary outcomes were safety and the change in apnea-hypopnea index (AHI) from baseline to 12 months postoperatively. Polysomnographic and quality of life outcomes were assessed at 1, 2, 6, and 12 months postoperatively. RESULTS: Among the 42 patients (28 male patients [66.7%]; mean [SD] age, 15.1 [3.0] years), there was a mean (SD) decrease in AHI of 12.9 (13.2) events/h (95% CI, -17.0 to -8.7 events/h). With the use of a therapy response definition of a 50% decrease in AHI, the 12-month response rate was 65.9% (27 of 41), and 73.2% of patients (30 of 41) had a 12-month AHI of less than 10 events/h. The most common complication was temporary tongue or oral discomfort, which occurred in 5 patients (11.9%). The reoperation rate was 4.8% (n = 2). The mean (SD) improvement in the OSA-18 total score was 34.8 (20.3) (95% CI, -42.1 to -27.5), and the mean (SD) improvement in the Epworth Sleepiness Scale score was 5.1 (6.9) (95% CI, -7.4 to -2.8). The mean (SD) duration of nightly therapy was 9.0 (1.8) hours, with 40 patients (95.2%) using the device at least 4 hours a night. CONCLUSIONS AND RELEVANCE: Upper airway stimulation was able to be safely performed for 42 adolescents who had Down syndrome and persistent severe OSA after adenotonsillectomy with positive airway pressure intolerance. There was an acceptable adverse event profile with high rates of therapy response and quality of life improvement. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02344108.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Yu PK, Stenerson M, Ishman SL, et al. Evaluation of Upper Airway Stimulation for Adolescents With Down Syndrome and Obstructive Sleep Apnea. JAMA Otolaryngol Head Neck Surg. 2022. PMID: 35446411. doi:10.1001/jamaoto.2022.0455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。